Skip to main content

Advertisement

Archived Comments for: Primary pancreatic leiomyosarcoma: a case report

Back to article

  1. Bedside diagnosing Pancreas Cancer , even in its inherited real Risk.

    Sergio Stagnaro, Quantum Biophysical Semeiotics Research Laboratory

    31 October 2008

    Editors,

    Notoriously, as referred in this interesting paper, the prognosis for individuals diagnosed with pancreatic carcinoma is poor, largely because diagnosis often comes after metastases have occurred, as in this case. As a matter of fact, in a lot of papers, one reads that pancreas cancer diagnosis is made, unfortunately later exclusively with the aid of instrumental and/or image semeiotics. In my opinion, based on 53-year-long clinical experience, overlooking Quantum Biophysical Semeiotics, there is a fundamental bias in such as researches, (See www.semeioticabiofisica.it , Practical Applications,) (1-8). Since 10 years, I am suggesting the central role played by the Oncological Terrain-dependent INHERITED oncological real Risk in primary prevention and treatment of cancer (1-10)

    Interestingly, in the normal pancreas microcirculatory bed (or better said, pancreas tissue-microvascular unit), analogously to that of lung, heart, stomach, oesophagus, mamma, a.s.o., there are exclusively type II, physiological, Endoarterial Blocking Devices (EBD), according to S.B.Curri, recognized at the bedside nowadays even with a stethoscope, thanks to Biophysical Semeiotics and Clinical Microangiology (www.semeioticabiofisica.it/microangiology.it, Physiology Page, and Pathology Page) (1-10). Numerous ureteral reflexes as well as the "simple", advisable from practical viewpoint, gastric aspecific reflex, allow doctor to bedside evaluate structure and function of microcirculatory bed diverse components. In health, we cannot observe newborn-pathological, type I, subtype a) oncological, and b) aspecific, EBD, but only type II, EBD, the only ubiquitous, in above-mentioned biological systems, including pancreas. On the contrary, in individuals, positive for Oncological Terrain "and" involved by oncological or other Inherited Real Risk (e.g., pancreas, coronary, oesophagous, breast, stomach, lung, prostate cancer or inflammatory-degenerative real risk) with the aid of Biophysical Semeiotics we observe also newborn-pathological, type I, subtype a) oncological, and/or b), common to all other disorders, EBD, facilitating since birth the proper diagnosis of whatever real risk, including pancreatic real risk, namely the very first stage of disease, that plays a pivotal role in primary prevention (1-10). Briefly, in individuals with a pancreas cancer congenital real risk, "intense" stimulation of the related trigger-points (i.,e., VI Thoracic Dermatomere) by lasting cutaneous pinching or digital pressure, brings about aspecific gastric reflex (= stomach dilates after "normal" latency time of 12 sec. in post-absorptive state (as regards pancreas, of course), but showing a pathological duration of more than 4 sec. (NN = lower than 4 sec.: interesting parameter value, correlated with Microcirculatory Functional Reserve, and consequently with presence and number of newborn-pathological EBD, according to my Angiopathy theory) (2). Interestingly, only in cancer congenital real risk, the reflex is followed by pathological tonic Gastric Contraction, absent in health and in all other non-oncological inherited real risk, including diabetes (7, 9). In addition, under identical experimental condition, exclusively when stimulation is intense, we observe middle ureteral reflex, lasting 20 sec. exactly, of 2 cm. of intensity, which disappears for 6 sec. precisely. Such as type I, sub-type a) oncological, newborn-pathological, EBD-dependent middle ureteral reflex persists characteristically even under "really intense" stimulation, indicating characteristically its oncological nature. On the contrary, under identical condition, type I, subtype b) aspecific, newborn-pathological EBD -dependent middle ureteral reflex, typical of biophysical-semeiotic real risk of all other common and severe human disorders (e.g.,diabetes), but not of malignancy, disappears almost completely (minus 2/3 of size) if stimulation becomes rapidly more intense, showing EBDdifferent muscular structure (7, 9). Fortunately, under the same condition, physicians may gather bedside such as data in above-described easy, reliable, and rapid way, evaluating the simple gastric aspecific reflex (1-10).

    REFERENCES.

    1) Stagnaro Sergio, Stagnaro-Neri Marina. Introduzione alla Semeiotica Biofisica. Il Terreno oncologico. Travel Factory SRL., Roma, 2004.

    http://www.travelfactory.it/semeiotica_biofisica.htm

    2) Stagnaro S., Stagnaro-Neri M., Le Costituzioni Semeiotico-Biofisiche.Strumento clinico fondamentale per la prevenzione primaria e la definizione della Single Patient Based Medicine. Ediz. Travel Factory, Roma, 2004. http://www.travelfactory.it/semeiotica_biofisica.htm

    3) Stagnaro S., Il dolore nella pancreatite acuta edematosa interstiziale. Com. IV Congr. Naz. AISD. Chieti-Pescara. Atti,1,V,3, 1980.

    4) Stagnaro S. Genes and Cancer: a clinical view-point. The Oncological Terrain. BioMed Central Informatics.2004. http://www.biomedcentral.com/1471-2105/5/21/comments#10454

    5) Stagnaro-Neri M., Stagnaro S., Pancreatite Acuta Edematosa Interstiziale. Diagnosi percusso-ascoltatoria. Acta Med. Medit. 3, 14

    6) Stagnaro Sergio. Bed-Side Prostate Cancer Detecting, even in early stages (“Real Risk” of Cancer): BMC Family Practice, 6:24 doi:10.1186/1471-2296-6-24 http://www.biomedcentral.com/1471-2296/6/24/comments#202466

    7) Stagnaro S. Newborn-pathological Endoarteriolar Blocking Devices in Diabetic and Dislipidaemic Constitution and Diabetes Primary Prevention. The Lancet. March 06 2007. http://www.thelancet.com/journals/lancet/article/PIIS0140673607603316/comments?totalcomments=18)

    8)Stagnaro Sergio. Clinical tool reliable in bedside early recognizing pancreas tumour, both benign and malignant. World Journal of Surgical Oncology 2005, 3:62 doi:10.1186/1477-7819-3-62

    9) Stagnaro S. New bedside way in reducing mortality in diabetic men and women. Ann. Int. Med. http://www.annals.org/cgi/eletters/0000605-200708070-00167v1

    10) Sergio Stagnaro Mitochondrial Bed-Side Evaluation: a new Way in the War against Cancer (21 December 2005). Cancer Cell

    Internationalhttp://www.cancerci.com/content/5/1/34/comments#218502

    Competing interests

    None declared

Advertisement